Semglutide’s Long Term Efficacy PICOT Paper

Author(s)

Title of Article

Year of publication 

Journal

Problem/Purpose

Design/Type

Of study

Instruments

Sample Description

Sample size

Findings

Chao, A. M., Quigley, K. M., & Wadden, T. A.

Dietary interventions for obesity: clinical and mechanistic findings.

2021

The Journal of Clinical Investigation, 131(1).

The study purpose was to find out whether lower-calorie diets, compared with higher-calorie regimens, can induce larger short-term (<6 months) weight losses, with deterioration of this benefit over the long term (>12 months).

Narrative Review of meta-analyses and select clinical trials found that 

Not indicated

Non because the study is a narrative review

Non because the study is a narrative review

There was ssignificant long-term differences in weight loss were observed for diets of varying macronutrient composition, although some regimens were found to have short-term advantages (e.g., low carbohydrate versus low fat)

Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., Hovingh, G. K., Jeppesen, O. K., Kokkinos, A., Lincoff, A. M., Meyhöfer, S. M., Oral, T. K., Plutzky, J., van Beek, A. P., Wilding, J. P. H., & Kushner, R. F.

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.

2024

Nature Medicine

, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI).

prespecified analysis

Clinical trials

Adults with preexisting cardiovascular disease, overweight or obesity, without diabetes.

17,604 adults

The study found that Semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. Weight loss was sustained over 4 years.

Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S. STEP TEENS Investigators.

Once-Weekly Semaglutide in Adolescents with Obesity

2022

N Engl J Med.

once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone

double-blind, parallel-group, randomized, placebo-controlled trial

BMI measuring tools

adolescents (12 to <18 years of age) with obesity

201 participants

According to the study, a once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group.

Once-Weekly Semaglutide in Adults with Overweight or Obesity

2021

N Engl J Med.

To find out whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to lifestyle intervention.

Double blind trial

BMI measuring tool

primary estimand (a precise description of the treatment effect reflecting the objective of the clinical trial) assessed effects regardless of treatment discontinuation or rescue interven

1961 adults

In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.